Abstract 369P
Background
Molecular profiling of tumour tissue to guide treatment of patients (pts) with advanced solid tumours has previously been reported. Most series were reported from large volume academic cancer centres in the West. There is a paucity of data reporting the experience and applicability of such an approach in Asia. We report our single-centre experience of conducting a prospective molecular profiling programme for pts in advanced solid tumours.
Methods
Pts with advanced solid tumours aged >/= 18 years, good performance status and archival tumour tissue available were prospectively consented. The RNA extracted from the FFPE tissue sections were subjected to RNA-sequencing using Archer FusionPlex Solid Tumor Kit and Archer Analysis Software 5.1. The putative gene translocations or alternative splicing were further confirmed with RT-PCR or FISH.
Results
253 pts consented between Feb 2017 and Feb 2019. Demographics: M:F 138 : 115; Median age = 58 (range: 19-89). Diseases included sarcomas (n = 88, 35%), NSCLC (n = 61, 24%), glioma (n = 42, 17%), melanoma (n = 7, 3%) and others (n = 55, 21%). Median turn-around time from consent to availability of report: 24 days (range: 3-112 days). 89% of samples passed quality control assessments. 8% (n = 21) of samples could not be processed due to insufficient material (n = 18), decalcified specimen (n = 2) and poor RNA quality (n = 1). 20 pts (9% of tested samples) had actionable genomic alterations identified that resulted in off-label use of directed anti-cancer therapies, referral to clinical trials or compassionate access programmes. These include EGFRvIII mutations (n = 7) and MET alterations (n = 2) in gliomas; ROS1 (n = 4), ALK (n = 2), MET exon 14-skipping (n = 1) and RET (n = 1) rearrangements in NSCLC; ALK rearranged sarcoma (n = 1). Across all diseases, 3 pts with NTRK fusions were identified.
Conclusions
We report the first institutional-based molecular profiling programme in Hong Kong. Such programmes are feasible in Asia. Pts can potentially benefit from identification of actionable alterations within a reasonable time frame and be channelled to appropriate therapies or clinical trials.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The Chinese University of Hong Kong.
Funding
F. Hoffmann-La Roche Ltd (formerly Ignyta Inc.).
Disclosure
H. Loong: Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (institution): Roche; Advisory / Consultancy: Celgene; Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Eli Lilly; Advisory / Consultancy, Travel / Accommodation / Expenses: Boehringer Ingelheim; Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Merck Sereno; Advisory / Consultancy, Speaker Bureau / Expert testimony: AbbVie; Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (institution): Bristol-Myers Squibb; Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Eisai; Speaker Bureau / Expert testimony: Guardant Health; Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Novartis; Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Bayer; Research grant / Funding (institution), Travel / Accommodation / Expenses: Merck Sharp & Dohme; Travel / Accommodation / Expenses: Pfizer; Advisory / Consultancy: Takeda ; Research grant / Funding (institution): Mundipharma. B.B.Y. Ma: Speaker Bureau / Expert testimony: Roche. E.P. Hui: Speaker Bureau / Expert testimony: Merck Sharp & Dohme; Speaker Bureau / Expert testimony: Merck Sereno; Advisory / Consultancy: Merck Sharp & Dohme; Research grant / Funding (institution): Merck Sharp & Dohme; Research grant / Funding (institution): Pfizer. All other authors have declared no conflicts of interest.
Resources from the same session
339TiP - PACIFIC-5: Phase III study of durvalumab after either concurrent or sequential chemoradiotherapy (CRT) in patients with stage III NSCLC
Presenter: Yi-Long Wu
Session: Poster display session
Resources:
Abstract
340TiP - A multicenter, randomized, controlled, phase II trial exploring adjuvant combined therapy of apatinib and SHR-1210 (anti-PD-1), in patients with hepatocellular carcinoma at high risk of recurrence after radical resection
Presenter: Shida Yan
Session: Poster display session
Resources:
Abstract
347P - Relationship between modified surgical margin and prognosis of cutaneous squamous cell carcinoma
Presenter: Yukiko Teramoto
Session: Poster display session
Resources:
Abstract
348P - Malignant melanoma: A study of clinical profiles and treatment outcomes in Indian patients
Presenter: Sorun Shishak
Session: Poster display session
Resources:
Abstract
349P - Flavonoids from ethanol extracts of euphorbia hirta inhibit melanoma growth and metastatic potential
Presenter: Shubhra Mishra
Session: Poster display session
Resources:
Abstract
350P - Low-dose cisplatin and 5-fluorouracil combined concurrent chemoradiotherapy for unresectable cutaneous squamous cell carcinoma: Analysis of 23 cases
Presenter: Azusa Hiura
Session: Poster display session
Resources:
Abstract
353P - A prediction model for the intents regarding life-sustaining treatment decisions in patients with terminal cancer
Presenter: Yoonsun Kim
Session: Poster display session
Resources:
Abstract
354P - Predictive factors and survival outcomes with stereotactic body radiation therapy in treatment of oligometastases in colorectal cancer
Presenter: Vibhay Pareek
Session: Poster display session
Resources:
Abstract
355P - Cost analysis and overview of single versus multiple fraction palliative radiotherapy for painful bone metastasis
Presenter: Vinodhkumar Selvaraj
Session: Poster display session
Resources:
Abstract
356P - Observational study on role of crude cannabis in pain control and quality of life in terminally ill cancer patients: An Indian perspective
Presenter: Vidyasagar Dusi
Session: Poster display session
Resources:
Abstract